You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Breast cancer

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

  • Technology appraisal guidance
  • Reference number: TA495
  • Published:  20 December 2017
  • Guidance
  • Tools and resources
  • Information for the public
  • History

On this page

  1. Final appraisal determination: 1
  2. Draft guidance
  3. Invitation to participate
  4. Draft scope documents

History

Documents created during the development process.

Final appraisal determination: 1

  • Final appraisal determination: 1

  • Final appraisal determination document (PDF 442 KB)

    Published:
    16 November 2017
  • Public committee slides ACM3 (PDF 644 KB)

    Published:
    16 November 2017
  • Public committee slides ACM2 (PDF 606 KB)

    Published:
    16 November 2017
  • Committee papers Equality Impact Assessment Form (PDF 235 KB)

    Published:
    16 November 2017
  • Committee papers (PDF 6.13 MB)

    Published:
    16 November 2017

Draft guidance

  • Draft guidance

  • Appraisal consultation document (PDF 424 KB)

    Published:
    03 February 2017
  • Committee papers (PDF 24.04 MB)

    Published:
    03 February 2017
  • Committee papers Clinical and Cost Effectiveness Presentation Slides (PDF 1.39 MB)

    Published:
    03 February 2017

Invitation to participate

  • Final scope (PDF 114 KB)

    Published:
    09 August 2016
  • Final matrix (PDF 100 KB)

    Published:
    09 August 2016
  • NICE's response to comments on the draft scope and provisional matrix (PDF 215 KB)

    Published:
    09 August 2016
  • Equality impact assessment (Scoping) (PDF 64 KB)

    Published:
    09 August 2016

Draft scope documents

  • Draft scope (pre-referral) (PDF 132 KB)

    Published:
    21 June 2016
  • Provisional matrix (pre-referral) (PDF 102 KB)

    Published:
    21 June 2016
Back to top